The landscape of migraine prevention has experienced relevant changes since the introduction of the monoclonal antibodies (mAbs) targeting the calcitonin gene-related (CGRP) peptide or the CGRP receptor (together referred to as CGRP-mAbs). This evidence concerns the gene CALCA and migraine disorder.